METHOD OF REDUCING THE INCIDENCE OF GASTROINTESTINAL SIDE EFFECTS DURING THE TREATMENT OF INFLAMMATORY ITIONS WITH ANTIINFLAMMOTORY DRUGS AND COMPOSITIONS THEREFOR

摘要

A method is disclosed for inhibiting and alleviating gastrointestinal side effects often encountered during thera?y with antiinflammatory agents such as indomethacin, phenylbutazone, oxyphenylbutazone, ibuprofen, mefenamic acid, ?lufenamic acid, naproxen, and the like. The method comprises the administration to a mammal receiving such therapy of a prostaglandin derivative of formula I, I in which (a) W is C = O, X and Y each are single bonds, Z is either C = O, CHOH or C(CH3)OH, R1 and R2 each are hydrogen, R3 is (CH2)3CH3, R4 is hydrogen or lower alkyl and R5 is hydrogen; (b) W is CHOH, X and Y each are single bonds, Z is either CHOH or C(CH3)OH, R1 and R2 each are hydrogen, R3 is (CH2)3CH3, R4 is hydrogen or lower alkyl and R5 is hydrogen; (c) W is C = O, X is a single bond, Y is a trans double bond, Z is CH2, CHOH or C(CH3)OH, R1 and R2 each are hydrogen and R3 is (CH2)3CH3, R4 is hydrogen or lower alkyl and R5 is hydrogen; (d) W is C = O, X is a single bond, Y is a trans double bond, Z is CHOH, R1 and R2 each are hydrogen, R3 is cyclohexyl, R4 is hydrogen or lower alkyl and R5 is hydrogen; (e) W is C = O, X is a cis double bond, Y is a trans double bond, Z is CHOH, or C(CH3)OH, R1 is hydrogen and R2 is hydrogen or methyl, R3 is (CH2)3CH3, R4 is hydrogen or lower alkyl and R5 is hydrogen; (f) W is C = O, X is a cis double bond, Y is a trans double bond, Z is CHOH, R1 and R2 each are methyl, R3 is (CH2)3CH3, R4 is hydrogen or lower alkyl and R5 is hydrogen; (g) W is C = O, X is a cis double bond, Y is trans double bond, Z is CHOH, R1 and R2 each are hydrogen or methyl, R3 is (CH2)3, R4 is hydrogen or lower alkyl and R5 is hydroxyl; or (h) W is C = O, X is a cis double bond, Y is a trans double bond, Z is C(CH3)OH, R1 and R2 each are hydrogen, R3 is (CH2)3, R4 is hydrogen or lower alkyl and R5 is hydroxyl. Also disclosed are useful pharmaceutical compositions for treating inflammatory conditions comprising a combination of a gastrointestinal side effect-inhibiting dose of the above prostaglandin derivative of formula I and a therapeutic dose of an antiinflammatory agent.